Purpose of Review Herein, we summarize existent epidemiological studies relating adverse maternal metabolic environments of maternal obesity and gestational diabetes and placental DNA methylation. Recent Findings Multiple studies have evaluated associations between intrauterine exposure to gestational diabetes and/or maternal glucose levels and DNA methylation at candidate metabolic genes as well as in epigenome-wide studies. Some of the genomic regions more consistently associated include lipid-related genes (LPL and PPARGC1A), the major histocompatibility complex (MHC), and imprinted genes. Studies solely focused on maternal obesity influences on the placental epigenome are scarce. Summary Understanding the placental mechanisms involved in fetal metabolic programming could lead to discovery of placental biomarkers at birth that predict later-life metabolic risk. Moving forward is important to standardize methods utilized in epigenetics research; consistent methodology can help interpret disparate findings. Larger studies with longitudinal follow-up are needed to address future challenges in fetal programming research.
Introduction

Obesity (body mass index [BMI] ≥ 30 kg/m
2 ) is a chronic inflammatory disease and arguably the most important public health problem of modern society. Worldwide, the prevalence of obesity has been alarmingly rising. Women, including those of reproductive age, do not escape this trend; in this group, the prevalence of obesity increased from 29% in 1980 to 38% in 2013 [1] . In the USA, more than one in five pregnant women were obese before being pregnant in 2009 [2] . Pre-pregnancy obesity is a risk factor for other pregnancy-related maternal comorbidities [3•, 4] including increased risk of gestational diabetes (GDM) [5] , preeclampsia [6] , miscarriage, stillbirth [7] and cesarean (C-section) delivery [8] . Similarly, newborns born to obese mothers are more likely to be large for gestational age (LGA) [9] , macrosomic [10] , preterm [11] , and have congenital malformations [12] . Moreover, pre-pregnancy obesity and GDM influence offspring susceptibility to disease beyond the perinatal period. Children and adults born from obese mothers are at increased risk of obesity and T2D later in life [4, 13, 14] , which perpetuates the problem into what has been called the intergenerational cycle of obesity and diabetes [15, 16] .
The Developmental Origins of Health and Disease Hypothesis (DOHaD) posit that suboptimal intrauterine conditions are associated with later-life disease risk. This paradigm was first derived in the 1980s by David Barker from epidemiological observations of higher cardiovascular disease risk (CVD) in individuals born with low birth weight (LBW) [17] . Subsequently, studies derived from the Dutch Famine Birth Cohort [18] reported associations between periconceptional exposure to famine and increased risk of reduced glucose tolerance [19] and obesity [20] in adulthood. Presently, a myriad of epidemiological studies in multiple populations have described associations between birth weight and later-life outcomes, particularly cardiovascular and metabolic disease [21] . Weight at birth is commonly used as a fetal growth proxy in DOHaD studies, particularly because of its amenability of measure, but also because it summarizes the intrauterine milieu provided by the maternal nutritional, hormonal, and metabolic environment.
The placenta is the central regulator of the intrauterine environment that mediates maternal-fetal physiological interactions. The placenta is the first organ to develop and is in charge of multiple functions including anchoring the embryo, nutrient, and waste delivery, immunological barrier, and endocrinological organ [22] [23] [24] . Placental development is intimately related and is essential for fetal development, but is also interrelated to the maternal environment [25] . Thus, the placenta is the crucial link between maternal physiology and fetal development and consequently is the central organ to study in the context of DOHaD [25] [26] [27] . Adverse intrauterine metabolic environments such as that of famine, maternal obesity, and/or gestational diabetes (GDM) can lead to permanent placental and fetal adaptations that could result maladaptive later in life leading to increased metabolic disease risk.
The molecular mechanisms involved in these maladaptive changes have proven elusive and hard to characterize, especially in humans. Nevertheless, it is clear that intrinsic genetic factors cannot explain all the latent effects because of their lack of environmental plasticity. Epigenetic mechanisms have been proposed as candidate molecular mediators in DOHaD because these integrate environmental signals into the control of gene expression. The principal mechanisms of epigenetic regulation are DNA methylation, histone modifications, and non-coding RNAs [28] . The environmental responsiveness of epigenetic mechanisms is best exemplified in the elegant studies conducted in Agouti mice [29] ; variability in DNA methylation upstream of the Agouti gene results in changes in body weight and fur color in otherwise genetically identical animals [30] . Moreover, DNA methylation at this locus can be influenced by changes in maternal nutrition and environmental exposures during early life [31] . Maternal nutrition has also been associated with placental epigenetic marks in humans, demonstrated in a small intervention study dose-response choline diet during the third-trimester of pregnancy. Higher choline diet increased placental global and promoter methylation of cortisol-related genes (CRH and NR3C1). However, these effects seem to be specific to certain genomic regions as other genes were not affected by nutritional supplementation [32] .
In this review, we summarize the existing evidence relating adverse metabolic environments of obesity and GDM to placental epigenetic variation in humans. We focused our attention on DNA methylation because this is the epigenetic mechanism most widely studied in epidemiological settings.
Candidate Gene Studies
Some of the genes evaluated in the epidemiological placental epigenetic programming literature come from associations between in utero famine exposure and candidate-gene methylation changes in blood DNA in the Dutch Famine Studies. This is the case of IGF2, LEP, ABCA1, INSIGF, IL10, LEP, GNASAS, and MEG3 [33, 34] , which were initially investigated because these were known to be imprinted or related to metabolism. Although all of these have been associated with perinatal famine exposure, only some have been evaluated in the context of GDM and maternal obesity in placental tissue. The results from these studies are summarized in Table 1 .
Metabolic Genes
One of the most studied famine-associated genes is leptin (LEP), an important adipokine involved in energy metabolism. The first cross-sectional study that evaluated placental LEP methylation profiled CpG DNA methylation within the LEP promoter region in 48 term placentas from a FrenchCanadian population [35] . The authors did not observe absolute differences in LEP methylation between placentas exposed to impaired glucose tolerance (IGT, N = 25) compared to normal glucose tolerance (NGT) (N = 23) pregnancies. The authors reported significant correlations between LEP DNA methylation and maternal glucose levels measured 2 h after a 75-g oral glucose tolerance test (2-h post-OGTT) performed at 24-28 weeks of gestation, only in women in the IGT group. Intriguingly, glucose levels showed a positive correlation with LEP methylation in the maternal side of the placenta and inverse correlation with LEP in the fetal side [35] . Importantly, this study by Bouchard et al. also found a negative correlation between placental LEP methylation and gene expression, as well as a positive correlation between placental LEP mRNA and maternal serum leptin levels during the 3rd trimester. In another study in a German population [36] , the authors evaluated DNA methylation at multiple candidate genes in relation to GDM, including LEP promoter methylation and did not observe differences in chorionic villi samples from diettreated GDM (N = 27) or insulin-treated GDM (N = 32) compared to non-GDM controls (N = 41). Our group has also investigated LEP promoter methylation in relation to maternal obesity and GDM in 535 term placentas from the Rhode Island Birth Cohort Study [37] . We observed placental LEP hypermethylation in 47 ). LPL methylation lower in GDM-exposed placentas. Placental LPL methylation correlated with birth weight z-scores (r = 0.252, P = 0.04), and with 5-year weight z-scores (r = 0.314, P = 0.01) and fat mass (r = 0.275, P = 0.04), and negatively correlated with lean mass (r = 0.306, P = 0.02). and r = − 0.20; P = 0.028, respectively).
LPL-CpG1
IGF1R mRNA associated with birth weight (r = 0.20; P = 0.032)
IGT impaired glucose tolerance, NGT normal glucose tolerance, GDM gestational diabetes mellitus, OGTT oral glucose tolerance test, wk. weeks, BMI body mass index, 2 h post-OGTT two hours after a 75-g oral glucose tolerance test
Concomitantly, pre-pregnancy obesity was also associated with higher placental LEP. Using structural equation modeling, we found that GDM act as significant mediator of the effects of pre-pregnancy BMI in placental LEP methylation. Importantly, our analyses accounted for potential confounders, particularly infant factors (sex and rs2167270 genotype) which we had previously described to influence placental LEP methylation [45] . Overall, the summary of existent placental LEP methylation in relation to GDM and maternal glucose levels shows contrasting results, future studies should evaluate this issue further and in different populations. In 2013, adiponectin (ADIPOQ), another important adipokine, was evaluated in a study involving 93 FrenchCanadian women, also conducted by the Bouchard group. Lower placental ADIPOQ promoter methylation was associated with higher maternal 2nd trimester glucose levels (2-h post-OGTT) and with higher insulin resistance index (2nd and 3rd trimesters). Importantly, lower ADIPOQ methylation was associated with higher maternal circulating adiponectin [38] . In the same year, this group also described results related to another metabolic gene, the ABCA1 (member 1 of human transporter sub-family ABCA), previously related to famine exposure and implicated in high-density lipoproteins cholesterol (HDL-C) metabolism. The study reports positive correlations between ABCA1 promoter DNA methylation in the maternal side of the placenta and maternal glucose levels (2 h post-OGTT) and circulating HDL-C. On the fetal side of the placenta, ABCA1 methylation was negatively correlated to cord blood triglyceride levels, but not to maternal values. Prominently, placental ABCA1 promoter methylation was inversely correlated to gene expression, suggesting a functional role for ABCA1 methylation [39] .
A later study also by Bouchard (2014) [40] described associations between placental DNA methylation at another lipid-related gene: the placental lipoprotein lipase (LPL). In an analysis including 27 GDM cases and 99 NGT controls, LPL DNA methylation was lower in placentas from infants exposed to a hyperglycemic environment. LPL methylation at CpG1 (promoter) and CpG3 (intron) methylation was negatively correlated to maternal glucose levels (2 h post-OGTT) and HDL-cholesterol, but not to gene expression. Interestingly, only methylation at the LPL intron 1, and not within the promoter, was negatively associated with gene expression. Notably, a more recent follow-up study [41•] reported positive associations between placental LPL DNA methylation and birth weight z-scores, weight z-scores, and fat mass at 5 years of age [41•] . Interestingly, both at birth and at the 5-year follow-up, children exposed to in utero to GDM had lower weight z-scores compared to non-exposed counterparts, which contrasts previous epidemiological associations between GDM and risk of LGA and macrosomia [46] and higher BMI in children [47] . However, the authors comment that women in this study received well-monitored medical treatment, which could help explain these results. A similar decrease in the rate of LGA and macrosomic births was recently reported in a large epidemiological study in the USA, which shows a reduction in these adverse fetal outcomes even when GDM incidence rates keep increasing, also arguing for the efficacy of currently implemented GDM treatment protocols [48] .
The PGC-1α is transcriptional coactivator encoded by PPARGC1A gene and involved in energy homeostasis and metabolism. Two recent studies evaluated PPARGC1A methylation in human placentas. A small Chinese study of 58 Han Chinese ancestry women observed a positive association between glucose levels (2nd trimester) and placental promoter PPARGC1A methylation, observed in all placentas regardless of GDM-exposure status [42] . Following these associations, Côté et al. also reported positive associations between PPARGC1A methylation and 2nd trimester fasting glucose and 2-h post-OGTT glucose, which were replicated in an independent cohort study also of French-Canadian ancestry (Gen3G). This study also surveyed other genes related to brown adipose tissue (BAT) and reported correlations between maternal glucose measures and PRDM16 methylation, as well as deferential BMP7 methylation between GDM-exposed and non-exposed placentas [43] .
The glucocorticoid receptor gene (NR3C1) has been previously shown as an environmentally responsive and epigenetically regulated with effects in metabolism and behavior in both rodents [49] and humans [50] . Importantly, placental NR3C1 hypermethylation is associated with LGA status [51] . Given the relation between GDM and LGA, it is not surprising that NR3C1 methylation could also relate to GDM. Only one study [36] has reported on placental NR3C1 methylation in relation to GDM, placentas exposed to both diet-treated GDM and insulin-treated GDM have significantly lower NR3C1 methylation compared to controls, a counterintuitive result especially after considering the previous LGA findings. Thus, additional research is needed to clarify if indeed NR3C1 methylation is related to GDM and/or LGA status.
Imprinted Genes
Genomic imprinting results in parent-of-origin-specific gene expression because DNA methylation silences the other allele. Imprinting is particularly important in the placenta where many genes exhibit tissue-specific imprinting and are related to fetal growth [52] . Moreover, blood methylation marks at imprinted loci (INSIGF, GNASAS, and MEG3) have been associated with famine exposure in the Dutch Famine Studies. Two studies have examined methylation at imprinted genes in the placenta in relation to maternal glucose levels. Recently, a study performed in French-Canadians reported that IGF1R and IGFBP3 methylation were significantly lower in placentas exposed to IGT and negatively correlated with glucose levels (2-h post-OGTT) [44] . A more recent and larger study, conducted in a Chinese population, observed similar results; placental IGF2 methylation was negatively associated with GDM status and infant macrosomia, correspondingly opposite results were described for IGF2 mRNA [53] .
Importantly, a German study reported that MEST is hypomethylated in placentas exposed to GDM [36] . IGF1R, IGF2, and MEST are paternally expressed genes, thus lower methylation levels are consistent with overgrow outcomes related to intrauterine hyperglycemia exposure.
Global DNA Methylation and Epigenome-Wide Association Studies
In Table 2 , we list studies evaluating global DNA methylation and epigenome-wide association studies (EWAS) related to GDM, maternal glucose levels, and/or maternal obesity and placental DNA methylation.
Two studies have evaluated global DNA methylation and adverse maternal metabolic environments [54, 55] . In a small pilot study (N = 50), our group assessed global DNA methylation using a semiquantitative luminometric assay in term placentas from a birth cohort in the New York metropolitan area. We observed lower DNA methylation in GDM placentas compared to non-GDM, whereas maternal obesity was associated with higher global DNA methylation compared to normal BMI, we also observed marginally significant hypomethylation in placentas exposed to pre-eclampsia [55] . A more recent and considerably larger study, conducted in Germany, used placentas from 1030 term pregnancies, measured global DNA methylation with liquid chromatography-electrospray ionization/multi-stage mass spectrometry (LC-ESI/MS/MS) and reported global hypermethylation in GDM placentas compared to non-GDM. Importantly, this study excluded preeclampsia cases from their analysis and adjusted for potential confounders including pre-pregnancy BMI [54] .
The first placental epigenome-wide study (EWAS) considering the effects of GDM was a small study including 14 controls and 30 GDM-exposed placentas from FrenchCanadian women. The authors report 781 differentially methylated genes (P value < 0.01) that were enriched for pathways related to cardiovascular and metabolic disease. However, none of the CpG loci evaluated reached genome-wide significance [56] . In follow-up analyses, the authors attempted to replicate 10 of the top loci in a different French-Canadian population, including 20 GDM-exposed placentas and 60 non-GDM controls [39] . However, they were unable to reproduce the initial EWAS findings. Nevertheless, they observed associations between glucose levels and methylation at BRD2, CACNA1D, and LRP1B in normoglycemic women [62] .
A more recent study by Finer et al. [57] used placental tissue from 48 South Asian origin women receiving antenatal care in a hospital in London (UK). Their findings report 1708 placenta methylation variable positions (MVPs) (FDR-adjusted P value < 0.05), > 5% of these changes were located within 1st exons, genes. These MVPs were enriched for pathways related to endocytosis, MAPK signaling, and extracellular triggers to intracellular metabolic processes. Concomitantly, the authors performed a parallel EWAS using cord blood methylation and describe some shared MVPs. However, none of the CpG loci reported by the authors had been identified in previous placental epigenetic GDM studies.
Another EWAS study [58] conducted in Nanjing (China) included 36 GDM-exposed and 40 control placentas. The authors report more than 6000 DMRs in 3000 differentially methylated genes as significant. However, this analysis was not adjusted for multiple testing or maternal and infant covariates. Subsequently, technical validation with bisulfite pyrosequencing and qPCR was performed for 4 metabolic-related genes (RBP4, GLUT3, Resistin, and PPARα). Methylation at GLUT3, Resistin, and PPARα were validated by bisulfite pyrosequencing; significant differences in placenta mRNA levels between GDM and controls were observed for GLUT3 and Resistin.
In 2015, Binder et al. conducted a GDM EWAS using 41 GDM-exposed and 41 control placentas from the Harvard Epigenetic Birth Cohort (HEBC) [59] . Both DNA methylation and gene expression changes were evaluated using arrays. Using a multiple-step approach, the authors first identified differentially methylated CpGs which were next prioritized using a bum-hunting approach. This strategy resulted in 4 regions to follow-up with pyrosequencing validation in an independent population in Rhode Island. One of these DMRs mapped to the major histocompatibility complex (MHC) region was marginally validated. Moreover, differential transcriptome-wide analyses in a subset of placentas also highlighted multiple differentially expressed genes in the MHC. The MHC region has also been associated through genome-wide association studies to type 1 diabetes (T1D) [63] , gestational diabetes in a Korean population [64] , and to a multitude of other immune-related outcomes [65] . These findings should be followed up in future studies that also integrate genetic variation to the DNA methylation analysis, especially since the MHC is the most polymorphic area of the genome [66] .
Recently, a large EWAS of glucose levels (2-h post-OGTT) and term placenta DNA methylation was performed in a population of 448 French-Canadians from the Genetics of Glucose regulation in Gestation and Growth Birth Cohort (Gen3G) [60] . Maternal glucose levels were associated with 7 CpG sites after FDR adjustment. Four of these CpGs mapped to PDE4B (phosphodiesterase 4B) gene, higher maternal glucose was associated with lower PDE4B methylation also associated with expression. Importantly, the authors attempted to replicate their findings in an independent birth Table 2 Global DNA methylation and epigenome-wide studies of gestational diabetes, maternal glucose and obesity Cell-type heterogeneity corrected results using the reference-free approach in the supplemental. 78 DMRs (P < 0.001) Findings in the MHC region partially validated in an independent cohort (RICHS).
MHC transcripts also different between GDM compared to non-GDM placentas. (ECO-2) ; however, none of the four loci evaluated replicated. The authors argued that CpGs within the PDE4B region had similar effect sizes for associations with maternal glucose and this might be due to decreased statistical power in the smaller replication dataset. To our knowledge, the only EWAS study conducted to date on maternal obesity and placental methylation was recently published by Mitsuya et al. [61] in a population from San Antonio, Texas. The authors report multiple differentially methylated and hydroxymethylated regions associated with maternal obesity. Similarly, they describe a 21% increase in methylated along with a 31% decrease in hydroxymethylated regions in placentas exposed to obesity compared to lean counterparts. Regions that showed differential methylation and hydroxymethylation were enriched for pathways related to pregnancy, immune response and cell adhesion-linked processes. Interestingly, the authors also evaluated placental metabolites and report a positive correlation between ascorbate and α-ketoglutarate.
To summarize the findings of existent studies, we compiled all the genes at which placental methylation changes have been associated with GDM, maternal glucose, and maternal obesity status (Fig. 1) . These include candidate genes and published EWAS results. Methylation at these genes does not correspond to a specific gene region, but to CpGs within or near these genes reported in these studies, we summarize the results at the gene level to maximize potential overlap. Only two genes have been associated in multiple studies. The insulin-like growth factor 1 receptor (IGF1R) gene (15q26.13) was first reported to be associated with GDM in Fig. 1 Chromosome ideogram illustrating genes for which a CpG methylation change has been reported to be associated with GDM, maternal glucose, or maternal obesity (Tables 1 and 2 ). Methylation changes locate within or near these genes. Data obtain from candidate gene studies (n = 12), Binder et al. 2015 (data from Table S2) a EWAS [56] and later followed up by the same group in a candidate gene study including a larger French-Canadian population [44] . The VIPR1 gene (3p22.1) encodes for the vasoactive intestinal polypeptide receptor 1, was first associated with GDM in 2013 in French Canadians [56] (GDM 15% vs. NGT 20% methylation; P = 7.3 × 10 −5
), and later associated with GDM in a US cohort study [59] (ß = 0.06, P = 6 × 10 −6 ), although with opposite effect direction between studies. However, some genomic regions show associations in multiple studies. For example, a region in chromosome 19 (1p13.3-19p.13) contains five genes (SIRT6, ADAMTSL5, RESISTIN, LDLR, and ZSWIM4) associated in at least four studies. Moving forward, future maternal obesity and GDM-related EWASs should provide summary statistics from association analyses; this is critical to enable future meta-analysis to identify consistent results and not isolated findings that appear in one study but not in others. Recent collaborative initiatives such as the Pregnancy and Childhood Epigenetics Consortium are starting to address this issue to move epigenetics research into larger sample sizes and reproducible results [67••] .
Conclusions and Future Perspectives
We have outlined the current state of the evidence pertaining between GDM and obesity and placental DNA methylation. We conclude: (1) associations between DNA methylation at candidate genes and placental exposure to GMD or glucose levels have been inconsistent with a few exceptions of glucose and lipid-related genes, the MHC and imprinted genes. (2) Placental EWAS studies investigating GDM or maternal glucose have not followed consistent rigorous methodology specifically as pertains to multiple testing correction and replication of the findings; however, more recent studies have started to recognize [68•] and change [60] these practices. (3) Only a few studies have assessed the effects of maternal obesity independently on placenta epigenetic marks; thus, there is a clear need for future focused studies; (4) placental epigenetic research related to GDM and maternal obesity will benefit from the inclusion of multiple more diverse populations and birth cohorts. (5)There is also a clear need to study possible mediating effects of these epigenetics marks in relation to later-life adverse metabolic outcomes; to this end, more longitudinal studies are needed.
The contribution of fetal metabolic programming to the rising incidence of chronic metabolic disease requires further studies to elucidate the mechanisms behind these phenomena. The epigenome is a likely mechanistic candidate, particularly when interrogated in functionally relevant tissues such as the placenta. Examining the impact of adverse maternal metabolic factors on placental epigenetic marks is particularly important given the current obesity epidemic and its possible consequences on later-life disease susceptibility. Placental epigenetic marks could help develop biomarkers at birth that prospectively predict metabolic risk which in turn can help design early prevention/intervention to reduce metabolic disease burden.
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